We are live on
!
Find out more
Marshall Wace Portfolio holdings
AUM
$100B
1-Year Est. Return
35.1%
This Fund
S&P 500
This Quarter
Est. Return
+1.13%
1 Year Est. Return
+35.1%
3 Year Est. Return
+111.04%
5 Year Est. Return
+146.93%
10 Year Est. Return
+631.22%
AUM
$10.4B
AUM Growth
-$279M
(-2.6%)
Cap. Flow
-$218M
Cap. Flow
% of AUM
-2.1%
Top 10 Holdings %
Top 10 Hldgs %
17.29%
Holding
1,364
New
413
Increased
268
Reduced
302
Closed
358
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Adobe
ADBE
|
+$105M |
| 2 |
EMC
EMC CORPORATION
EMC
|
+$103M |
| 3 |
iShares MSCI Emerging Markets ETF
EEM
|
+$97.6M |
| 4 |
Alphabet (Google) Class A
GOOGL
|
+$77.4M |
| 5 |
Humana
HUM
|
+$71.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$125M |
| 2 |
Perrigo
PRGO
|
+$103M |
| 3 |
AGN
Allergan plc
AGN
|
+$99.6M |
| 4 |
Pfizer
PFE
|
+$90M |
| 5 |
Viatris
VTRS
|
+$88.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Discretionary | 15.63% |
| 2 | Healthcare | 15.57% |
| 3 | Communication Services | 13.26% |
| 4 | Technology | 11.56% |
| 5 | Financials | 9.69% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CELG
301
DELISTED
Celgene Corp
CELG
| $6.09M | 0.06% |
60,811
+55,705
| +1,091% | +$5.74M |
|
|
RLYP
302
DELISTED
RELYPSA INC COM
RLYP
| $6.08M | 0.06% |
+448,773
| New | +$7.63M |
|
303
W.R. Berkley
WRB
$28B
| $6.08M | 0.06% |
364,834
+133,967
| +58% | +$2.06M |
|
304
Greif
GEF
$4.47B
| $6.04M | 0.06% |
184,306
-104,809
| -36% | -$2.89M |
|
305
Carlisle Companies
CSL
$13.6B
| $6.03M | 0.06% |
60,553
-14,554
| -19% | -$1.28M |
|
306
Skyworks Solutions
SWKS
$9.06B
| $6M | 0.06% |
77,040
+23,829
| +45% | +$1.62M |
|
307
American International
AIG
$41.9B
| $6M | 0.06% |
111,027
-572,704
| -84% | -$30.9M |
|
308
InterDigital
IDCC
$6.68B
| $5.93M | 0.06% |
106,602
-35,091
| -25% | -$1.69M |
|
|
MRSH
309
Marsh
MRSH
$86.3B
| $5.93M | 0.06% |
97,568
-38,626
| -28% | -$2.16M |
|
310
Murphy USA
MUSA
$11.3B
| $5.93M | 0.06% |
96,475
+84,299
| +692% | +$5.19M |
|
311
Paycom
PAYC
$6.78B
| $5.9M | 0.06% |
165,644
+21,748
| +15% | +$679K |
|
|
FOE
312
DELISTED
Ferro Corporation
FOE
| $5.9M | 0.06% |
496,689
-261,358
| -34% | -$2.62M |
|
|
ISEE
313
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $5.89M | 0.06% |
139,298
+21,334
| +18% | +$1.09M |
|
314
Scorpio Tankers
STNG
$3.96B
| $5.79M | 0.06% |
99,376
-73,178
| -42% | -$4.34M |
|
315
Baxter International
BAX
$11.6B
| $5.79M | 0.06% |
+140,838
| New | +$5.37M |
|
316
Silgan Holdings
SLGN
$4.91B
| $5.78M | 0.06% |
+217,484
| New | +$5.65M |
|
317
Lincoln Electric
LECO
$13.8B
| $5.75M | 0.06% |
+98,226
| New | +$5.35M |
|
318
BGC Group
BGC
$5.58B
| $5.74M | 0.06% |
+986,963
| New | +$5.67M |
|
|
VISN
319
Vistance Networks Inc
VISN
$2.66B
| $5.68M | 0.05% |
203,554
+154,638
| +316% | +$3.75M |
|
|
CNL
320
DELISTED
CLECO CRP (HOLDING CO)
CNL
| $5.63M | 0.05% |
101,983
+66,096
| +184% | +$3.36M |
|
|
NFX
321
DELISTED
Newfield Exploration
NFX
| $5.63M | 0.05% |
169,276
-243,675
| -59% | -$6.87M |
|
322
International Paper
IP
$22.3B
| $5.62M | 0.05% |
144,685
-219,660
| -60% | -$7.65M |
|
323
CF Industries
CF
$19.2B
| $5.61M | 0.05% |
179,063
-444,457
| -71% | -$14.5M |
|
324
KLA
KLAC
$275B
| $5.6M | 0.05% |
+769,050
| New | +$5.17M |
|
325
Danaher
DHR
$135B
| $5.57M | 0.05% |
87,346
+74,159
| +562% | +$4.42M |
|
Similar funds
Marshall Wace's Q1 2016 Portfolio in Review
As of Q1 2016, Marshall Wace held 1,364 positions worth $10.4B, down 2.6% from $10.7B the previous quarter. Its ten largest holdings account for 17% of the portfolio.
Marshall Wace's Q1 2016 filing shows 413 new, 268 increased, 302 reduced and 358 closed positions. Its largest new stake was iShares MSCI Emerging Markets ETF: 3,149,620 shares worth $108M. The largest sale was Bristol-Myers Squibb, an estimated $125M.
By sector, the portfolio is most concentrated in Consumer Discretionary at 16% of assets, up from 12% a quarter earlier, followed by Healthcare and Communication Services.
- Marshall Wace's largest Q1 2016 buy was iShares MSCI Emerging Markets ETF: 3,149,620 shares worth $108M.
- Marshall Wace added most to Adobe in Q1 2016, an estimated $105M increase.
- Marshall Wace's biggest Q1 2016 reduction was Bristol-Myers Squibb, cutting an estimated $125M.
- Marshall Wace fully exited Perrigo in Q1 2016, selling an estimated $103M.
- Marshall Wace's ten largest holdings make up 17% of its $10.4B portfolio in Q1 2016.
- Marshall Wace opened 413 new positions and closed 358 in Q1 2016.
- Marshall Wace's portfolio value fell 2.6% quarter-over-quarter to $10.4B.
Based on Marshall Wace's 13F filing for Q1 2016, filed 13 May 2016.